These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 36598376)

  • 1. Compound heterozygosity for novel von Willebrand factor genetic variants associated with von Willebrand disease in two Chinese patients.
    Wang Y; Wang X; Lu Y; Zhang A; Yu W; Hu Q; Liu A; Huang JF
    Blood Coagul Fibrinolysis; 2023 Jan; 34(1):33-39. PubMed ID: 36598376
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
    Gadisseur A; Berneman Z; Schroyens W; Michiels JJ
    Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Laboratory diagnosis and molecular classification of von Willebrand disease.
    Gadisseur A; Hermans C; Berneman Z; Schroyens W; Deckmyn H; Michiels JJ
    Acta Haematol; 2009; 121(2-3):71-84. PubMed ID: 19506352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of recessive severe type 1 and 3 von Willebrand Disease (VWD), asymptomatic heterozygous carriers versus bloodgroup O-related von Willebrand factor deficiency, and dominant type 1 VWD.
    Michiels JJ; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van de Velde A; van Vliet H
    Clin Appl Thromb Hemost; 2006 Jul; 12(3):277-95. PubMed ID: 16959681
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bleeding prophylaxis for major surgery in patients with type 2 von Willebrand disease with an intermediate purity factor VIII-von Willebrand factor concentrate (Haemate-P).
    Michiels JJ; Berneman ZN; van der Planken M; Schroyens W; Budde U; van Vliet HH
    Blood Coagul Fibrinolysis; 2004 Jun; 15(4):323-30. PubMed ID: 15166918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recessive von Willebrand disease type 2 Normandy: variable expression of mild hemophilia and VWD type 1.
    Michiels JJ; Gadisseur A; Vangenegten I; Schroyens W; Berneman Z
    Acta Haematol; 2009; 121(2-3):119-27. PubMed ID: 19506358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization, classification, and treatment of von Willebrand diseases: a critical appraisal of the literature and personal experiences.
    Michiels JJ; Gadisseur A; Budde U; Berneman Z; van der Planken M; Schroyens W; van de Velde A; van Vliet H
    Semin Thromb Hemost; 2005 Nov; 31(5):577-601. PubMed ID: 16276467
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Von Willebrand factor propeptide and pathophysiological mechanisms in European and Iranian patients with type 3 von Willebrand disease enrolled in the 3WINTERS-IPS study.
    Pagliari MT; Rosendaal FR; Ahmadinejad M; Badiee Z; Baghaipour MR; Baronciani L; Benítez Hidalgo O; Bodó I; Budde U; Castaman G; Eshghi P; Goudemand J; Karimi M; Keikhaei B; Lassila R; Leebeek FWG; Lopez Fernandez MF; Mannucci PM; Marino R; Oldenburg J; Peake I; Santoro C; Schneppenheim R; Tiede A; Toogeh G; Tosetto A; Trossaert M; Yadegari H; Zetterberg EMK; Peyvandi F; Federici AB; Eikenboom J
    J Thromb Haemost; 2022 May; 20(5):1106-1114. PubMed ID: 35092343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of von Willebrand factor phenotypes and genotypes in Hemophilia A patients with and without identified F8 mutations.
    Boylan B; Rice AS; De Staercke C; Eyster ME; Yaish HM; Knoll CM; Bean CJ; Miller CH;
    J Thromb Haemost; 2015 Jun; 13(6):1036-42. PubMed ID: 25780857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dominant von Willebrand disease type 2M and 2U are variable expressions of one distinct disease entity caused by loss-of-function mutations in the A1 domain of the von Willebrand factor gene.
    Gadisseur A; van der Planken M; Schroyens W; Berneman Z; Michiels JJ
    Acta Haematol; 2009; 121(2-3):145-53. PubMed ID: 19506361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reevaluation of von Willebrand disease diagnosis in a Croatian paediatric cohort combining bleeding scores, phenotypic laboratory assays and next generation sequencing: a pilot study.
    Lapić I; Radić Antolic M; Dejanović Bekić S; Coen-Herak D; Bilić E; Rogić D; Zadro R
    Biochem Med (Zagreb); 2022 Feb; 32(1):010707. PubMed ID: 35210927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation between von Willebrand factor antigen, von Willebrand factor ristocetin cofactor activity and factor VIII activity in plasma.
    Lippi G; Franchini M; Salvagno GL; Montagnana M; Poli G; Guidi GC
    J Thromb Thrombolysis; 2008 Oct; 26(2):150-3. PubMed ID: 17786534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dominant von Willebrand disease type 2A groups I and II due to missense mutations in the A2 domain of the von Willebrand factor gene: diagnosis and management.
    Michiels JJ; van Vliet HH
    Acta Haematol; 2009; 121(2-3):154-66. PubMed ID: 19506362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
    Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U
    Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An evaluation of the DDAVP infusion test with PFA-100 and vWF activity assays to distinguish vWD types in children.
    Akin M; Karapinar DY; Balkan C; Ay Y; Kavakli K
    Clin Appl Thromb Hemost; 2011 Oct; 17(5):441-8. PubMed ID: 20460340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Similarity in joint and mucous bleeding syndromes in type 2N von Willebrand disease and severe hemophilia A coexisting with type 1 von Willebrand disease in two Chinese pedigrees.
    Qin HH; Xing ZF; Wang XF; Ding QL; Xi XD; Wang HL
    Blood Cells Mol Dis; 2014 Apr; 52(4):181-5. PubMed ID: 24351655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Desmopressin therapy to assist the functional identification and characterisation of von Willebrand disease: differential utility from combining two (VWF:CB and VWF:RCo) von Willebrand factor activity assays?
    Favaloro EJ; Thom J; Patterson D; Just S; Dixon T; Koutts J; Baccala M; Rowell J; Baker R
    Thromb Res; 2009 Apr; 123(6):862-8. PubMed ID: 19064279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. von Willebrand factor variant p.Arg924Gln marks an allele associated with reduced von Willebrand factor and factor VIII levels.
    Hickson N; Hampshire D; Winship P; Goudemand J; Schneppenheim R; Budde U; Castaman G; Rodeghiero F; Federici AB; James P; Peake I; Eikenboom J; Goodeve A;
    J Thromb Haemost; 2010 Sep; 8(9):1986-93. PubMed ID: 20492463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Next-generation sequencing of von Willebrand factor and coagulation factor VIII genes: a cross-sectional study in Croatian adult patients diagnosed with von Willebrand disease.
    Lapić I; Radić Antolic M; Boban A; Coen Herak D; Rogić D; Zadro R
    Croat Med J; 2022 Apr; 63(2):166-175. PubMed ID: 35505650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Compound Heterozygosis of Two Novel Mutations in vWF Exacerbates vWD in a Chinese Pedigree.
    Hu J; Yu H; Wang W; Li J; Xu Q; Rong J; Lu S
    Clin Lab; 2024 Feb; 70(2):. PubMed ID: 38345986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.